The primary objective of this study is to evaluate the efficacy and safety of lowering lipoprotein(a) through RNA interference with olpasiran in participants with atherosclerotic cardiovascular disease and elevated lipoprotein(a) concentrations. OCEAN(a)-Outcomes (TIMI 75) on ClinicalTrials.gov CONTACT US about OCEAN(a)-Outcomes